ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Boehringer acquires Northern Biologics, collaborates with CDR-Life

by Michael McCoy
May 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

 

The German drug maker Boehringer Ingelheim has acquired Northern Biologics, a Canadian developer of antibodies targeting the tumor microenvironment, for an undisclosed sum. One of Northern’s two experimental antibodies inhibits a key protein in the microenvironment, causing a tumor to become susceptible to immune system attack. Separately, Boehringer will collaborate with the Swiss firm CDR-Life on developing antibody fragment therapies that treat geographic atrophy, a retinal disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment